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Summary 
Thymic epithelial cells can produce many kinds of cytokines, and interleukin 
(IL)-6-producing thymic carcinoma cases have been reported. However, a 
cytokine-producing human thymic tumor cell line has not previously been established. 
In this paper, we report a novel, multiple inflammatory cytokine-productive cell line 
that was established from a patient with thymic carcinoma. This cell line, designated 
ThyL-6, positively expressed epithelial membrane antigen, cytokeratins, vimentin 
intermediate filament, and CD5, although hematological markers were not present in the 
cells. Cytokine antibody array analysis showed that the cells secreted several cytokines 
including IL-1α, IL-6, IL-8, RANTES, soluble TNFα-receptor 1, VEGF, and CTLA 
into the culture medium. The addition of ThyL-6-cultured supernatant supported the 
growth of human myeloma ILKM-3 cells, which require the presence of IL-6 in the 
culture medium for the maintenance of cell growth, suggesting that the secreted IL-6 
from ThyL-6 cells was biologically active. Chromosome analysis demonstrated that 
ThyL-6 cells w complex karyotype anomalies, including der(16)t(1;16); the latter has 
been recognized in thymic squamous cell carcinoma and thymic sarcomatoid carcinoma 
cases, as well as in several other kinds of malignancies. Heterotransplantation of the 
cells into nude mice showed tumorigenesis with neutrophil infiltration and liquefactive 
necrosis. These findings suggest that ThyL-6 cells will provide us with a new 
experimental tool for investigating not only the pathogenesis, biological behavior, 
chromosomal analysis, and therapeutic reagents of human thymic carcinoma, but also 
for studying cytokine-chemokine network systems. 
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Introduction 
The thymus is known to develop multiple types of neoplasms including 
thymomas, germ cell tumors, neurogenic tumors, lymphoblastic leukemias/ lymphomas, 
and other tumors. Thymic epithelial tumors are rare, but are the most common neoplasm 
of the anterior mediastinum. Thymoma shows an indolent course, thymic carcinoma 
exhibits a heterogeneous group of aggressive epithelial malignancies,1, 2 and the 
epithelial tumors are divided into 11 subtypes in the WHO classification.3 Biologically, 
human thymic epithelial cells have been shown to produce many cytokines, including 
interleukin (IL) -1α, IL-3, IL-6, IL-7, IL-8, granulocyte macrophage-colony stimulating 
factor (GM-CSF), G-CSF, M-CSF, leukemia inhibitory factor, and transforming growth 
factor α, that are likely to contribute to thymocyte differentiation.4, 5 This ability carries 
with it a risk of developing various cytokine-producing tumors from the thymic 
epithelial neoplasms. In fact, several case reports have described the existence of IL-6 
producing thymic carcinomas.6, 7 On the other hand, no cytokine-producing human 
thymic epithelial tumor cell line has yet been reported, only a mouse thymic stromal cell 
line which produced M-CSF and IL-6.8 
Recently, we established and characterized a new inflammatory 
cytokine-producing cell line, ThyL-6, derived from a patient with thymic carcinoma. 
Because the establishment of cell lines is important for the investigation of the 
pathophysiological characteristics of diseases, biochemical analysis, and drug discovery, 
as well as the production of bio sources, the establishment of a ThyL-6 cell line would 
contribute to the investigation of the pathogenesis and biological behavior of thymic 
carcinoma, therapeutic reagents against it, and the study of cytokine-chemokine network 
systems. To our knowledge, ThyL-6 is the first cytokine productive human thymic 
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carcinoma cell line. 
 
Materials and Methods 
Patient. 
A 57-year-old male without a history of smoking was admitted to The 
University of Fukui Hospital because of a mediastinal tumor and leukocytosis. 
Histological inspection was performed by his primary doctor, and he was pathologically 
diagnosed as having undifferentiated thymic carcinoma. His complete blood cell counts 
showed leukocytosis with a 27,200 / μl white blood cell (WBC) count with 90% mature 
neutrophils, normocytic anemia with a 2.35 x 106 / μl red blood cell count, and 
thrombocytosis with 63.2 x 104 / μl of platelets, respectively. Body temperature was 
elevated above 38 °C and serum C-reactive protein (CRP) was increased to 32.6 mg/dl. 
Serum uric acid level was low, in the range between 1.7 and 2.3 mg/dl, whereas the 
serum creatinine level was within the normal range. A uric acid clearance test 9 showed 
an excess of uric acid excretion, with a urate clearance (Cua) of 18.2 ml/min, an 
excretion of uric acid (Eua) of 0.438 mg/kg/h, and a creatinine clearance (Ccr) of 122 
ml/min. Serum interleukin-6 levels measured by Enzyme Immuno Assay (EIA) were 
increased to 298 pg/ml. The serum levels were dependent on the tumor size because the 
value was reduced after chemotherapy. Despite several courses of antineoplastic 
chemotherapies, the tumor progressed and the patient died of pleuritis carcinomatosa. 
Informed consent was obtained from the patient a family member for this research work, 
and this research was approved by the ethics/institutional review board of The 
University of Fukui Hospital and conforms to the provisions of the declaration of 
Helsinki in 1995. 
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Reagents. 
RPMI 1640 medium, fetal bovine serum (FBS), 10% trypsin-EDTA, and an 
MTT assay kit were purchased from Sigma (St. Louis, MO, USA). A TranSignal Human 
Cytokine Antibody Array 3.0 kit was purchased from Panomics (Redwood City, CA, 
USA). Recombinant human IL-6, IL-8, and Regulated upon Activation, Normal T-cell 
Expressed, and Secreted (RANTES) were purchased from PeproTech EC (London, UK). 
An anti-human rabbit polyclonal IL-6 antibody, a monoclonal mouse IL-8 antibody 
(6217.11), and a goat polyclonal RANTES antibody were obtained from Sigma. 
Anti-human monoclonal CEA (Clone; II-7), EMA (E29), pan-cytokeratin (Pan CK) 
(AE1/AE3), CK 5/6 (D5/16 B4), CK 7 (OV-TL 12/13), CK 8 (35βH11), CK 10 
(DE-K10), CK 18 (DC 10), CK 19 (BA17), CK 20 (Ks20.8), melanosome (HMB-45), 
placental alkaline phosphatase (PLAP) (8A9), vimentin (V9), CD5 (CD5/54/F6), 
CD20cy (L26), CD30 (Ber-H2), CD45 (leukemia common antigen, LCA) 
(2B11+PO7/26), CD45R0 (UCHL-1), polyclonal CD117, and S100 antibodies were 
acquired from DAKO (Kyoto, Japan). Secondary HRP conjugated against mouse, goat, 
and rabbit IgG were obtained from Santa Cruz (Santa Cruz, CA, USA) and a BM 
Chemiluminescence Western Blotting Kit was purchased from Roche (Indianapolis, IN, 
USA). For immunohistochemical staining, a HISTOFINE SAB-PO kit (Nichirei, Tokyo, 
Japan) was used for the secondary reaction. Other general reagents were of the highest 
purity commercially available.  
 
Animal. 
 6-week-old male nude mice (BALB/c nu/nu, Sankyo Labo, Tokyo) were 
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subcutaneously inoculated in the back with 1 x 106 ThyL-6 cells. Two weeks later, the 
mice were sacrificed and pathological sections were prepared as described previously 10. 
The slide sections were stained by hematoxylin and eosin dye, 11 and the histological 
findings were evaluated by two different pathologists. Immunohistochemical staining of 
paraffin-embedded sections was performed as described previously 12. 
 
Cell culture. 
 Tumor cells were harvested from the pleural effusion and were cultured in 
RPMI 1640 medium supplemented with 10% FBS, penicillin, and streptomycin in a 5% 
CO2 atmosphere at 37 °C. The established cell line was designated as ThyL-6. Cell 
growth was evaluated by trypan-blue dye exclusion assay or MTT assay according to 
manufacturer’s protocol. The exponentially growing cells were used for several 
experiments. To determine cytokine secretion into the culture medium from the cells, 
the supernatants were collected at the confluent growth phase and stored at -80 °C until 
analysis. A human multiple myeloma ILKM-3 cell line (kindly provided by Dr. S. 
Shimizu, Shimane Prefectural Central Hospital),13 which requires IL-6 for cell growth, 
was used for the biological assay. 
 
Immunohistochemical staining. 
To explore the characteristics of the ThyL-6 cells, cells attached to an 
8-chamber slide (Nalge Nunc International, Tokyo, Japan) were fixed using 10% 
formaldehyde for 8 min. The fixed cells were incubated for 30 min with TBS (pH 7.6) 
in the presence of 10% FBS and 5% BSA to protect them from the non-specific binding 
of antibodies. The cells were incubated with anti-human primary antibodies and 
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visualized using a HISTOFINE SAB-PO kit according to the manufacturer’s 
instructions. 
 
Chromosome analysis. 
For identification of the chromosomes in the ThyL-6 cells, the exponentially 
growing cells were harvested and their karyotypes were analyzed according to the 
standard protocol of the Giemsa-banding technique. 
 
Human cytokine antibody array. 
 A TranSignal Human Cytokine Antibody Array 3.0 kit was used to investigate 
the secreted cytokine profiles of the ThyL-6 cells. The array membrane was incubated 
for 2 h at room temperature in the presence of 2 ml of the supernatant in which the 
ThyL-6 cells had been cultured for 4 days. The membrane was reacted with 
biotin-conjugated anti-human cytokine antibodies and then incubated with 
streptavidine-conjugated HRP. Secreted cytokines were visualized by a 
Chemiluminescence Image Analyzer (Alpha Innotech, San Leandro, CA, USA) and a 
BM Chemiluminescence Western Blotting Kit. Quantitative determination of cytokines 
in the culture medium was performed by EIA using the standard protocol. 
 
Western blotting. 
 For Western blotting analysis, the supernatant was directly loaded onto a 10% 
or 15% of SDS-PAGE gel with 2 x SDS-PAGE sample buffer (100mM Tris-HCl pH 6.8, 
4% SDS, 20% Glycerol, 20% β-mercaptoethanol, and 0.02% Bromophenol blue). In 
some experiments, the supernatant was concentrated by an Ultrafree-MC 10000 NMWL 
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Filter Unit (Millipore, Bedford, MA, USA) before sample loading. Separated proteins 
were transferred onto Immobilon-P 0.45 μm PVDF membrane (Millipore) and probed 
with specific antibodies in TBS-T (25 mM Tris, pH 8.4 supplemented with 130 mM 
NaCl, 5 mM potassium phosphate, 5% non-fat dry milk, and 0.1% Tween 20) as 
described previously.14, 15 Secondary antibodies conjugated to HRP, and a BM 
Chemiluminescence Western Blotting Kit were used to develop images in a 
Chemiluminescence Image Analyzer. 
 
Results 
ThyL-6 cell line shows epithelial cell differentiation. 
 Thymic neoplasms include thymomas, germ cell tumors, carcinoid tumors, 
lymphoblastic leukemias/lymphomas, neuronal tumors and other tumors. To clarify the 
origin of the cell line, an immunohistochemical stain was performed. As shown in 
Figure 1, the cells expressed the epithelial cell markers EMA, Pan CK, CK5/6, CK 7, 
CK19, CK20, mesenchymal filament vimentin, and CD5, whereas hematological 
antigens including CD20cy, CD30, CD45, and CD45R0, as well as CEA, melanosome, 
and PLAP antigens were not detected in the cells. Immunostaining data from the 
ThyL-6 cells with additional antibodies is summarized in Table 1. 
 
ThyL-6 produces multiple inflammatory cytokines and chemokines. 
 Interleukin 6 is associated with many reactions including the induction of 
inflammation, fever generation, thrombocytosis, increase of CRP, and promotion of uric 
acid excretion.16-19 The patient had the following clinical symptoms: high body 
temperature, thrombocytosis, high CRP value, hypouricemia, and high serum IL-6 level, 
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suggesting that the established thymic carcinoma cells were also producing 
inflammatory cytokines, especially IL-6. Therefore, we investigated the profile of 
cytokine production using a cytokine antibody array. After incubating the cells in 
culture medium for 96 hours, the resulting supernatant was found to contain IL-6, IL-8, 
RANTES, IL-1α, vascular endothelial growth factor (VEGF), soluble TNFα-receptor I 
(sTNFR I), and small amounts of eotoxin and cytotoxic T lymphocyte antigen (CTLA) 
(Figure 2). We then measured the cytokine concentrations of IL-6, IL-8, RANTES, 
IL-1α, VEGF, sTNFR I and eotoxin by EIA. The concentrations of IL-6, IL-8, 
RANTES, IL-1α, VEGF, and sTNFR I were 88,800 ± 3,111 pg/ml (normal serum level 
(nsl): ≤ 2.41 pg/ml), 88,350 ± 15,203 pg/ml (nsl: < 8.0 pg/ml), 526 ± 237 pg/ml (nsl: not 
determined), 502 ± 132 pg/ml (nsl: < 7.8 pg/ml), 9,625 ± 1,803 pg/ml (nsl: ≤ 38.3 
pg/ml), 542 ± 57 pg/ml (nsl: 434 - 930 pg/ml), respectively, whereas eotoxin was not 
detected by EIA (Table 2). In addition to EIA, we stained IL-6, IL-8, and RANTES 
using immunohistochemical techniques and found that these cytokines were localized in 
the cytoplasm (Figure 3). Although Apo1/Fas, Eotoxin, IP-10, Leptin, MMP3, 
ICAMP-1, IL-4, IL-7, and IL-12 were faintly detected by the cytokine antibody array, 
we considered them as being background levels already present in either the culture 
medium or FBS. GM-CSF, EGF, MIP1α, MIP 1β, MIP-4, MIP-5, TGF β, IFN γ, TNFR 
II, VCAMP-1, IL-1β, IL-1Rα, IL-2, IL-3, IL-5, IL-6R, IL-10, IL-15, and IL-17 could 
not be detected by the cytokine antibody array (Figure 2). 
 
Chromosomal analysis of ThyL-6 cells. 
In the cytogenetic analysis of ThyL-6 cells, twenty metaphases were 
investigated using the G-band technique. This cell line had two modes of chromosomes, 
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with the number of chromosomes being 51. The consistent karyotype aberrations were 
51, XY, +3, i(3) (q10), +7, add(7)(q11), dic(7)t(7;17)(p11;p11), +8, add(8)(p11), 
i(8)(q10), -9, -13, +15, i(15)(q10), der(16)t(1;16)(q11;q24), der(16)t(9;16)(q11;q24), 
add(21)(p11), der(?)t(?;q11), +2mar [18] / 51, idem, -der(?)t(?;q11), +mar [2] (Figure 
4). 
 
Cell growth of ThyL-6 is associated with the autocrine mechanism of IL-6. 
The growth rate of the ThyL-6 cells was evaluated by the trypan-blue dye 
exclusion method, and the doubling time was calculated at 26.3 h (Figure 5A). Several 
cytokines including IL-6, G-CSF, and GM-CSF can stimulate cell proliferation of 
normal marrow cells as well as several cancer cell lines by autocrine or paracrine 
mechanisms. To investigate the relevance of autocrine growth, ThyL-6 cells were 
cultured in the presence of neutralizing anti-human IL-6 or IL-8 antibody, and the 
growth inhibition was evaluated using an MTT assay. As shown in Figure 5B, the 
growth of ThyL-6 cells was dose-dependently inhibited in the presence of the anti-IL-6 
or IL-8 antibody, and the final volume increase of 10% when the IL-6 antibody was 
added to the medium exhibited a significant growth inhibition (35.7 ± 5.2% inhibition 
of untreated control, p<0.05), indicating that cell proliferation was partially dependent 
on the autocrine stimulation of IL-6. 
 
The produced IL-6 was biologically active. 
 Because the produced IL-6 was likely to be biologically active, we first 
compared the molecular weight of the produced IL-6 with that of recombinant human 
IL-6 using Western blotting. As shown in figure 6A, the molecular weight of the 
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produced IL-6 was slightly higher than the recombinant protein. When the expressions 
of IL-8 and RANTES were also compared, the molecular weights of these chemokines 
were almost the same as those of the recombinant proteins (data not shown). Next, we 
analyzed the growth of a human multiple myeloma cell line, ILKM-3, because the 
proliferation of the cells depends on the existence of IL-6 in the culture medium. When 
the supernatant of the cultured ThyL-6 cells was added to RPMI 1640 medium, the level 
of growth of the ILKM-3 cells was found to depend on the dose of the culture medium 
added (Figure 6B). 
 
Histological findings of ThyL-6 cells in nude mice. 
To evaluate the tumorigenesis in vivo, 1 x 106 of ThyL-6 cells were inoculated 
subcutaneously into 11 nude mice. Two weeks later, tumors developed in all of them 
(Figure 7A, 7B). The mice were sacrificed and both paraffin-embedded sections and 
frozen sections were prepared. As shown in Figures 7C and 7D, the polymorphic cells 
had round or oval nuclei with a large round nucleolus and these cells invasively 
proliferated into the backs of the mice with small amounts of interstitial fibrous 
connective tissue and scattered liquefactive necrosis present. In addition, neutrophils 
also infiltrated into the tumor nests independent of necrotic tissue. Similar histological 
findings containing mature granulocytes had been found in the original biopsy sections 
of the patient (data not shown), suggesting that the ThyL-6 is characterized by the 
induction of neutrophils-infiltration into the tumor nest. 
 
Discussion 
In the present study, we established and characterized a new cancer cell line 
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derived from a patient with undifferentiated thymic carcinoma who had markedly high 
levels of leukocytosis and thrombocytosis, a high CRP level, a low serum uric acid 
value, and a high serum IL-6 level. The epithelial nature of ThyL-6 cells was supported 
by the presence of cellular cytokeratins and EMA, which are known to be specifically 
expressed in epithelial cells.4, 20 Several multiple cytokine-producing cell lines have 
been previously reported involving G-SCF, GM-SCF, IL-6, IL-8, and other 
cytokines.21-25 Regarding inflammatory cytokines, several cell lines secrete both IL-6 
and IL-8,26, 27 and human cervical epithelial cell lines immortalized in retroviral 
constructs are known to produce IL-6, IL-8, and RANTES.28 Similarly, we found that 
ThyL-6 cells expressed cytoplasmic IL-6, IL-8, and RANTES. In addition, this cell line 
also secreted IL-1α, sTNFR I, VEGF, and CTLA into the culture medium. Importantly, 
human thymic epithelial cells have been shown to produce many cytokines, including 
IL-1α, IL-3, IL-6, IL-7, IL-8, G-CSF, GM-CSF, M-CSF, leukemia inhibitory factor, and 
transforming growth factor α, that are likely to contribute to thymocyte differentiation.4, 
5 Several reports mention that c-Kit (CD117) is a promising diagnostic marker with 80% 
of thymic carcinomas positive for it. 29, 30 In contrast, ThyL-6 cells do not express the 
marker. However, the histology of the tumor in nude mice corresponded well to that of 
the Ty-82 thymic carcinoma cells and was compatible with the morphological 
diagnostic criteria of thymic carcinoma, i.e., with large cell size, prominent nucleoli, 
high nuclear/cytoplasmic ratio, abundant mitosis, and multifocal confluent necrosis. 10 
In addition, the patient had never smoked. These data suggest that ThyL-6 is a multiple 
inflammatory cytokine-producing thymic carcinoma derived cell line. 
Overproduction or injection of IL-6 leads to acute inflammatory reactions, 
including fever and a high CRP level. Our patient suffered from a hyper CRP value of 
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more than 30 mg/dl, documented fever, hyperleukocytosis, and thrombocytosis, which 
allowed us to surmise that the patient had an increased serum IL-6 level. In fact, serum 
IL-6 level was significantly increased in this patient. Using EIA, immunohistochemical 
staining, and Western blotting, the established ThyL-6 cells were also verified as being 
able to produce IL-6. Moreover, the secreted IL-6 was shown to be biologically active 
because the growth of IL-6-dependent ILKM-3 cells was supported in the presence of 
the supernatant in which the ThyL-6 cells were cultured, suggesting that ThyL-6 can 
produce a bioavailable grade of human IL-6. 
Cytogenetic studies on thymic epithelial tumors are few, and the significance of 
chromosomal abnormalities is unknown, except for t(15;19)(q15;p13), which is possibly 
related to thymic carcinoma in children and young adults.31 A thymic cancer cell line 
with t(15;19)(q15;p13), Ty-82, has been established from a patient with undifferentiated 
thymic carcinoma 10, and the cell line exhibits EMA without showing any epithelial 
markers including cytokeratins. Whereas, ThyL-6 cells showed several epithelial 
markers including EMA, Pan CK, CK 5/6, 7, 8, 18, 19, and 20. In the CKs, CK 5/6 is 
preferentially expressed in epithelial cells differentiating toward squamous cells.32, 33 In 
addition, ThyL-6 cells represented CD5, which is expressed in thymic carcinoma, 
including thymic squamous cell carcinomas and rare cases of thymoma. Recently, 
several reports mention that some pulmonary squamous cell carcinoma cases also 
express CD5.29, 30 Taken together with the results, the expression of this molecule in 
ThyL-6 cells suggests that this cell line may have squamous cell potency. 
 Genetic analysis, based on comparative genomic hybridization of a relatively 
large number of thymoma and thymic carcinomas, has demonstrated that aggressive 
type B3 thymoma and thymic squamous cell carcinoma preferentially show aberrance 
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karyotypes with a gain of chromosome 1q.34 In the present case, ThyL-6 cells had 
complex chromosome abnormalities, and showed a 1q gain with the 
der(16)t(1;16)(q11;q24) chromosome in them. Abnormalities of 1q, including trisomy or 
partial gain of the arm, have been demonstrated to be the most frequent genetic changes 
in malignant cells,35, 36 and potentially important growth promoting genes have been 
demonstrated to map to 1q.35 Chromosome 16 is involved in unbalanced whole arm 
translocations as a counterpart of chromosome 1,36 and often constitutes a derivative 
chromosome, der(16)t(1;16). Der(16)t(1;16) abnormality has been recognized in several 
tumors including a multiple myeloma,37 myelodysplastic syndrome,38 Wilms’ tumor,39 
myxoid/round cell liposarcoma,40 breast carcinoma,41 Ewing’s sarcoma,42 alveolar 
rhabdomyosarcoma,36 and malignant peripheral nerve sheath tumor with 
rhabdomyoblastic differentiation.43 Regarding thymocytic tumors, this aberrant 
derivative chromosome formation has been reported in thymic squamous cell carcinoma 
and thymic sarcomatoid carcinoma cases.44, 45 Thus, these results suggest that 
der(16)t(1;16) may also play a significant role in the pathophysiology of thymic 
carcinoma as well as many kinds of malignancies. In addition, cell growth of ThyL-6 
cells showed a dose-dependent inhibition after the addition of neutralizing IL-6 antibody. 
The ThyL-6 cells had another chromosomal translocation on chromosome 17p11, which 
involves a pseudogene of human gp130 transducer chain gene of IL-6.46 Therefore, this 
cell line may also be useful for studying the autocrine growth mechanisms of IL-6, the 
IL-6 receptor, or reactivation of the pseudogene. 
In conclusion, we established a new multiple inflammatory cytokine-producing 
cell line. To our knowledge, this is the first such human thymic carcinoma cell line that 
produces inflammatory cytokines. Although further study is needed, this cell line could 
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provide us with a new experimental tool for investigating not only the pathogenesis, 
biological behavior, chromosomal analysis and therapeutic reagents of thymic 
carcinoma, but also for studying cytokine-chemokine network systems. 
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Table 1. Immunohistochemical Staining of ThyL-6 Cells
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Data represents mean ± SD from 2 different experiments. 
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Table 2. Secreted Cytokine Concentrations of ThyL-6 Cells
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Figure legends. 
 
Figure 1. Immunohistochemical staining of ThyL-6 cells. To investigate the expression 
profiles of ThyL-6 cells, the cells were attached to an 8-chamber slide and were treated 
with several primary antibodies and then visualized using a HISTOFINE SAB-PO kit 
according to the manufacturer’s protocol. CEA: carcinoembryonal antigen, CK: 
cytokeratin, EMA: epithelial membrane antigen, PLAP: placental alkaline phosphatase. 
 
Figure 2. Cytokine secretion profiles in ThyL-6 cell line detected by a cytokine antibody 
array. The supernatant in which ThyL-6 cells had been cultured for 4 days was collected 
and the secreted cytokine profiles were detected using a TranSignal Human Cytokine 
Antibody Array 3.0 kit. RPMI 1640 with 10% FBS was used as an untreated control. 
The lower panel represents the list of cytokines plotted on the array membrane. neg: 
negative control, pos: positive control. 
 
Figure 3. Immunohistochemical staining of inflammatory cytokines. Cells attached to 
an 8-chamber slide were fixed with 10% formaldehyde, and the cells were stained with 
anti-human IL-6, IL-8, or RANTES antibodies, respectively, and then visualized using a 
HISTOFINE SAB-PO kit. 
 
Figure 4. Chromosome analysis of ThyL-6 cells. The typical karyotype of ThyL-6 cells 
was 51, XY, +3, i(3) (q10), +7, add(7)(q11), dic(7)t(7;17)(p11;p11), +8, add(8)(p11), 
i(8)(q10), -9, -13, +15, i(15)(q10), der(16)t(1;16)(q11;q24), der(16)t(9;16)(q11;q24), 
add(21)(p11), der(?)t(?;q11), +2mar [18] / 51, idem, -der(?)t(?;q11), +mar [2]. 
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Figure 5. (A) Cell growth curve of ThyL-6 cells. 1 x 105 cells/ml of ThyL-6 cells were 
cultured in RPMI 1640 medium with 10% FBS, and the cell growth was evaluated by 
the trypan-blue dye exclusion method. Data represent the mean ± SD of triplicate 
cultures. (B) Growth inhibition of ThyL-6 cells in the presence of neutralizing 
antibodies. Trypsinized exponential growing cells were seated on a 96-well plate at a 
concentration of 1 x 105 cells and incubated overnight. Following the pre-incubation, 
the cells were washed three times with PBS and resuspended in fresh medium including 
neutralizing IL-6 or IL-8 antibodies at a final concentration of 10%, 1%, or 0.1% of 
culture medium. The cells were incubated for an additional 24 h, and the growth 
inhibition was investigated using an MTT assay. Data represent the mean ± SD of 
triplicate cultures. * indicates growth rate significantly decreased (p<0.05) in 
comparison with that of the untreated control cells. CTR: control, Ab: antibody. 
 
Figure 6. (A) Western blotting detection of IL-6 in the cultured supernatant of ThyL-6 
cells. The supernatant was resolved with 15% of SDS-PAGE, and the separated proteins 
were transferred onto PVDF membrane. The membrane was incubated with anti-human 
IL-6 monoclonal antibody. Secondary antibodies conjugated to HRP and a BM 
Chemiluminescence Western Blotting Kit were used to develop images in a 
Chemiluminescence Image Analyzer. (B) Cell growth of IL-6-dependent ILKM-3 cells 
in the presence of condition medium of ThyL-6 cells. Cells were cultured in RPMI 1640 
medium with 10% FBS in the presence or absence of appropriate concentrations of 
ThyL-6 condition medium. Cell growth was detected by an MTT assay kit. The 
percentage of ThyL-6 condition medium shown represents the final concentration in the 
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culture medium. Data represent the mean ± SD from three independent experiments. 
 
Figure 7. Heterotransplantation of ThyL-6 cells into a nude mouse. (A) A representative 
view of tumor (arrow) in the back of a nude mouse. (B) Cross-section of subcutaneous 
tumor mass lesion in a nude mouse. (C) A microscopic examination of the tumor 
produced in a nude mouse (low power magnification view) with hematoxylin and eosin 
staining. Tumor cells had proliferated with small amount of interstitial fibrous 
connective tissue. Liquefactive necrotic tissue was seen in the tumor mass (arrow head). 
(D) High power magnification view of the established tumor. Polymorphic cells with 
round or oval nuclei and a large round nucleolus had proliferated by mitosis, and 
neutrophils had infiltrated into the tumor nests. 
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